Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study
| Autor: | Sergio Coccheri, V. Zamboni, E. Palazzini, Giancarlo Agnelli, G. Scondotto |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Placebo-controlled study Urology Placebo Double-Blind Method Fibrinolytic Agents medicine Humans Aged Glycosaminoglycans Analysis of Variance Vascular disease business.industry Anticoagulant Fibrinogen Heparin Intermittent Claudication Middle Aged medicine.disease Sulodexide Intermittent claudication Surgery Treatment Outcome Italy Female medicine.symptom Cardiology and Cardiovascular Medicine Claudication business medicine.drug |
| Zdroj: | European heart journal. 23(13) |
| ISSN: | 0195-668X |
| Popis: | Aims Patients with peripheral arterial obstructive disease require treatment to prevent major cardiovascular events and to relieve intermittent claudication. The walking performance of peripheral arterial obstructive disease patients was used to evaluate the usefulness of sulodexide, a glycosaminoglycan containing fast moving heparin and dermatan sulphate. Methods and Results A randomized, multicentre, double-blind, placebo-controlled study was performed in 286 patients with Leriche-Fontaine stage II peripheral arterial obstructive disease. Patients received placebo (n=143) or sulodexide (n=143) for 27 weeks. The primary end-point was the doubling of the pain-free walking distance at the end of treatment, and this was achieved by 23·8% of patients treated with sulodexide and 9·1% of those on placebo ( P =0·001). The pain-free walking distance increased on average (±SE) by 83·2±8·6m (+64·7% from baseline) with sulodexide and 36·7±6·2m (+29·9% from baseline) with placebo ( P =0·001). The maximum walking distance increased by 142·3±15·8m (+76·0% from baseline) and 54·5±8·4m (+27·9% from baseline) ( P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|